Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Friday.

MCRB has been the topic of a number of other reports. JPMorgan Chase & Co. cut shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Canaccord Genuity Group restated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Thursday, November 14th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Stock Up 7.4 %

Shares of Seres Therapeutics stock traded up $0.06 during trading on Friday, reaching $0.91. The company’s stock had a trading volume of 1,518,476 shares, compared to its average volume of 1,304,388. The business has a 50 day moving average price of $0.82 and a 200-day moving average price of $0.90. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $2.05. The company has a market capitalization of $154.59 million, a P/E ratio of -3.94 and a beta of 2.07.

Institutional Investors Weigh In On Seres Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in MCRB. Virtu Financial LLC grew its stake in Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 18,191 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after purchasing an additional 255,014 shares during the last quarter. State Street Corp increased its stake in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares in the last quarter. Providence Wealth Advisors LLC raised its position in shares of Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 22,250 shares during the last quarter. Finally, FMR LLC lifted its stake in Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after buying an additional 140,096 shares in the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.